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As cases of COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2), continue to spread globally, public health
experts have warned about the devastating impact this pandemic
may have on society’s most vulnerable [1]. Meanwhile, another
public health crisis, the opioid epidemic, rages on throughout the
United States [2,3]. In other parts of the world, the use of opiates
and opioids has remained relatively stable; however, in Eastern
Europe, Russia and Central Asia opiate use has increased [4]. In
these regions, the prevalence of injection drug use is high, as is
prevalence of HIV among people who inject drugs – over 40% in
major Russian cities according to recent estimates [5]. Worldwide nearly half a million people died as a result of drug misuse
in 2015; 168,000 of those deaths were due to overdose [6]. People living with HIV (PLWH) face higher risk of opioid misuse than
HIV-negative people, in part because PLWH are more likely to
suffer chronic pain and receive opioid analgesic treatment for
symptom relief [7,8].
People who use drugs (PWUD) face unique vulnerabilities in
the COVID-19 era, including elevated homelessness and frequent interaction with criminal justice systems [9]. In the United
States alone, approximately four million people experiencing
homelessness cycle in and out of a variety of high-risk settings,
including street encampments, shelters, jails and prisons. Each of
these contexts present significant challenges to limiting the
spread of COVID-19. On the streets, for example, the very supplies needed to follow World Health Organization (WHO) recommended hand hygiene guidelines [10], including access to
clean water, soap and hand sanitizer, are scarce. Prison overcrowding, which was an international health concern prior
COVID-19 [11], has reached a crisis point. Limited COVID-19
testing in correctional settings, scarce PPE for inmates and staff
and COVID-19 outbreaks in prisons across the world make
incarcerated PWUD especially vulnerable for COVID-19 infection and resulting negative health outcomes [12].

For PWUD in community settings, disruptions in global supply chains and implementation of physical distancing measures
in response to the COVID-19 pandemic may limit access to
drugs and harm reduction services. The popular press has
documented limited availability of fentanyl and other synthetic
opioids due to closings of chemical manufacturing plants in
Wuhan, China [13]. Rising nationalism evidenced by policies
banning pharmaceutical and PPE exports, such as those instituted by the United States and India [14 ], and border closings,
such as those implemented in South America [15], may
decrease the availability of certain drugs, including synthetic
opioids. Whether disruptions in the drug supply chain are real
or imagined, the fear experienced by PWUD has an immeasurable effect on their wellbeing. In addition, harm reduction programmes, including naloxone distribution and syringe
exchange, have become increasingly difficult to access under
“shelter in place” restrictions [16].
So what can community advocates, researchers and
international stakeholders do to address COVID-19 vulnerability among PWUD? A comprehensive policy response
must be multi-pronged and dedicated to improving public
health programmes that serve PWUD and the communities
in which they live. Investment in public health infrastructure needs to incorporate investment in addressing social
determinants of health, including homelessness. In France,
temporary homeless shelters have opened across the country to accommodate those unable to shelter in place [17].
A recent analysis estimated that 400,000 new beds are
needed to meet the emergency accommodation and social
distancing needs of the single adult homeless population in
the United States on a given day during the COVID-19
pandemic [18]. Investment in temporary housing needs is
paramount for effectively addressing COVID-19 among
PWUD.
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Decriminalization of PWUD and access to harm reduction
services for PWUD must also be prioritized during the
COVID-19 pandemic. Scholars have called for police and
courts to immediately suspend arresting and sentencing people for low-level crimes and misdemeanors [19], which often
include possession of drugs. Over 70 countries worldwide
have introduced syringe exchange programmes [20] and naloxone has saved tens of thousands of lives in the United States
alone [21]; however, access to these harm reduction services
remains difficult in many countries. Anticipated scarcity of syringes and other injection equipment during the COVID-19
pandemic may prompt PWUD to share syringes or experiment
with new drugs or new drug use habits. To prevent outbreaks
of HIV, HCV and other infectious diseases among PWUD, policy makers in nations with high rates of opioid use, including
Russia and other Eastern European and Central Asian countries where new COVID-19 cases are beginning to surge [22],
would be wise to consider implementing government-supported programmes to purchase and allocate syringes. WHOendorsed naloxone distribution and training programmes
should be re-considered in contexts where harm reduction
programmes are outlawed [6].
Finally, because various physical distancing measures in
response to COVID-19 are anticipated to remain in place for
the foreseeable future, PWUD may have difficulty accessing
healthcare services, including opioid substitution therapy, medication-assisted treatment and other substance use treatment
services. Telemedicine has been successfully implemented during other global emergencies [23] and presents a key opportunity for helping PWUD stay connected to services while
protecting themselves against COVID-19 infection. PWUD in
greatest need will require sustained access to technology that
allows them to leverage telemedicine to facilitate engagement
with critical healthcare services, including continuous contact
with counsellors and addiction medicine specialists. In Canada,
opioid substitution therapy is prescribed and administered
through daily dispensing at pharmacies or as a take-home
medication [24]. During the COVID-19 pandemic some governments have recommended home delivery of HIV medications [25]; similar considerations for opioid substitution
therapy and medication-assisted treatment may be possible in
certain contexts. Uninterrupted access to cellular and internet
service will also be crucial to the success of these programmes.
As highlighted here, PWUD are especially vulnerable to
COVID-19 given their increased risk for homelessness, interactions with criminal justice systems and need to access inperson services for substance use treatment. International
leaders should consider programmes and policies outlined
here in order to avoid a more concentrated epidemic of
COVID-19 among PWUD. Millions of lives across the globe
depend on it.
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